Skip to Main content Skip to Navigation
Journal articles

Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis.

Abstract : Prevalence of non-alcoholic steatohepatitis (NASH) rises steadily in Western countries with the obesity epidemic. NASH is associated with activation of liver fibrogenesis and predisposes to cirrhosis and associated morbi-mortality. The cannabinoid system is increasingly emerging as a crucial mediator of acute and chronic liver injury. Recent experimental and clinical data indicate that peripheral activation of cannabinoid CB1 receptors promotes insulin resistance and liver steatogenesis, two key steps in the pathogenesis of non-alcoholic fatty liver disease. Moreover, CB1 receptors enhance progression of liver fibrogenesis. These findings provide a strong rationale for the use of CB1 antagonists in the management of NASH.
Document type :
Journal articles
Complete list of metadatas

Cited literature [19 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00371854
Contributor : Georges Guellaen <>
Submitted on : Monday, March 30, 2009 - 3:55:04 PM
Last modification on : Wednesday, August 19, 2020 - 11:17:01 AM
Long-term archiving on: : Saturday, November 26, 2016 - 7:06:16 AM

Files

inserm-00371854_edited.pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Ariane Mallat, Sophie Lotersztajn. Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis.. Diabetes and Metabolism, Elsevier Masson, 2008, 34 (6 Pt 2), pp.680-4. ⟨10.1016/S1262-3636(08)74604-4⟩. ⟨inserm-00371854⟩

Share

Metrics

Record views

447

Files downloads

975